Compare Inovio Pharmaceuticals Inc (INO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Under Armour Inc Class A trades at $7.18 (market cap $3.07B). The key difference: Under Armour Inc Class A is far larger — about 34.4× Inovio Pharmaceuticals Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | UA | |
|---|---|---|
Market Cap | $89.27M | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $7.88 |
52-Week Low | $1.05 | $3.96 |
Enterprise Value | $60.28M | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $201.27 million for 2025, with revenue of $5.16 billion, and faces declining revenue projections for 2026. Recent news includes a Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
The outlook remains challenged by negative profitability and cash flow, though analyst consensus leans slightly bullish with 40.3% buy ratings. Key risks include sustained revenue declines and high debt, while potential upside hinges on successful execution of premium product focus and inventory management strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
